Full metadata record
DC FieldValueLanguage
dc.contributor.authorPletscher, Mark-
dc.contributor.authorMattli, Renato-
dc.contributor.authorReich, Oliver-
dc.contributor.authorvon Wyl, Agnes-
dc.contributor.authorWieser, Simon-
dc.date.accessioned2018-03-01T09:18:10Z-
dc.date.available2018-03-01T09:18:10Z-
dc.date.issued2015-
dc.identifier.issn1091-4358de_CH
dc.identifier.issn1099-176Xde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/3359-
dc.description.abstractObjectives The Objectives of this study are to estimate the prevalence of schizophrenia in Switzerland and to assess its burden on patients, caregivers and society as a whole. Methods A hospital registry was combined with a physician survey and health insurance claims data to capture all patients living in the northern part of the canton of Zurich. Total costs included direct medical and non-medical costs and lost production. All costs were calculated for the year 2012 from a societal perspective using a prevalence-based bottom-up approach. Intangible costs were expressed as quality adjusted life years (QALY) lost and were calculated from Swiss life tables, standardized mortality ratios and utility weights from the literature. Uncertainty and its sources were addressed in univariate and probabilistic sensitivity analysis. Results The point prevalence of schizophrenia in 2012 was estimated at 0.39% of the Swiss population. The average annual costs of schizophrenia amounted to EUR 39,408 per patient and consisted of direct medical costs of EUR 9,507 (24%), the costs of care by relatives and in residential homes of EUR 4,793 (12%) and lost production of EUR 25,108 (64%). Inpatient hospital care accounted for EUR 6,242 per year or 66% of direct medical costs. The estimated reduction in life expectancy of 10.46 years and the utility decrement of 22.05 percentage points lead to intangible costs of 19.02 QALY per incident chronic case. Conclusions The Results of this study show the high burden of schizophrenia on patients, caregivers and society as a whole. The high costs of inpatient hospital care demonstrate the benefits of an effective prevention of relapse associated with hospitalization. Programs for the reintegration of schizophrenic patients into the labor market have a high potential to reduce the costs of schizophrenia considering the high burden of lost production and the early onset of the disease.de_CH
dc.language.isoende_CH
dc.publisherInternational Center of Mental Health Policy and Economicsde_CH
dc.relation.ispartofThe Journal of Mental Health Policy and Economicsde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectSchizophreniade_CH
dc.subjectCost of illnessde_CH
dc.subjectSwitzerlandde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.subject.ddc616.89: Psychische Störungen, klinische Psychologie und Psychiatriede_CH
dc.titleThe societal costs of schizophrenia in Switzerlandde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementAngewandte Psychologiede_CH
zhaw.organisationalunitPsychologisches Institut (PI)de_CH
dc.identifier.doi10.1016/j.jval.2014.08.1253de_CH
zhaw.funding.euNode_CH
zhaw.issue2de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end103de_CH
zhaw.pages.start93de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume18de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.webfeedKlinische Psychologiede_CH
Appears in collections:Publikationen Angewandte Psychologie

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.